Baxter Pharma India sets up global Pharmaceuticals RnD Centre in Ahmedabad

The 20,500-square-foot, state-of-the-art R&D Centre features an array of sophisticated equipment and research labs that will focus on pharmaceutical product development and capabilities in therapeutic areas such as critical care, analgesic, renal, cardiovascular anesthesia, anti-infective and antipyretic.

Published On 2022-10-19 05:30 GMT   |   Update On 2022-10-19 05:30 GMT
Advertisement

Ahmedabad: Baxter Pharmaceuticals India Pvt. Ltd. has announced the inauguration of a global Pharmaceuticals R&D Centre in Ahmedabad, India. The R&D Centre was inaugurated by Alok Sonig, President, Pharmaceuticals, Baxter International Inc. He was accompanied by Dr. Mahesh Chaubal, Vice President, Pharmaceuticals R&D, Baxter International Inc., and Dr. Sanju Dhawan, Director of R&D, Baxter Pharmaceuticals India Pvt. Ltd. in Ahmedabad.

Advertisement

Commenting on the occasion, Alok Sonig, President, Pharmaceuticals, Baxter International Inc. said, "Our world-class Ahmedabad R&D Centre is critical to unleashing the full power of our Pharmaceuticals pipeline and helping us advance patient care worldwide through differentiated injectable products to be commercialized globally."

The 20,500-square-foot, state-of-the-art R&D Centre features an array of sophisticated equipment and research labs that will focus on pharmaceutical product development and capabilities in therapeutic areas such as critical care, analgesic, renal, cardiovascular anesthesia, anti-infective and antipyretic. It will support Baxter's global manufacturing facilities, including those in Ahmedabad, Germany, Ireland, Italy, and the United States, among others.

This Pharmaceuticals R&D Centre is part of Baxter's network of more than 25 global R&D centers, including 4 in the APAC region.

"The COVID-19 pandemic has further highlighted the critical importance of increasing access to healthcare and providing affordable, quality medicines. Our team in India, particularly those working in the Ahmedabad Pharmaceuticals R&D Centre, will play an integral role in advancing our pipeline, expanding our products to new markets, and innovating to continue responding to the needs of patients all over the world," said Dr. Mahesh Chaubal, Vice President, Pharmaceuticals R&D, Baxter International Inc.

Dr. Sanju Dhawan, Director - R&D, Baxter Pharmaceuticals India Pvt. Ltd. Ahmedabad, said, "This R&D expansion broadens our presence in India while also acknowledging the country's specialised capabilities and potential. We are delighted with the diverse pool of talent that the Pharmaceuticals R&D Centre has, and we anticipate that it will attract even more talented professionals in the near future. This Centre is indeed a significant step forward to achieve our mission to save and sustain lives by meeting the unmet needs of patients in India and throughout the world through innovation."

Read also: Baxter launches cardiovascular medicine Norepinephrine in premix formulation in US

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News